Project Grant HT9425261E012
- The Medical University of South Carolina (MUSC) was awarded a $792,245 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "LEVERAGING LINEAGE ADDICTION: NUCLEAR DELIVERY OF THERAPEUTIC TRANSGENES RESPONSIVE TO ONCOGENIC TRANSCRIPTION FACTOR OVEREXPRESSION," will fund research focused on developing innovative gene therapy approaches to treat various medical conditions. The award has a performance...
- The Defense Health Agency awarded a $755,001 Project Grant to The Medical University of South Carolina (MUSC) under the Military Medical Research and Development program (CFDA 12.420). The three-year grant, running from July 1, 2023 to June 30, 2026, supports research on microsomal glutathione transferase as a new target in melanotic melanoma. As a public institution of higher education, MUSC conducts biomedical research and provides healthcare services, with a mission to preserve and optimize...
- Federal Grant Award Summary The Medical University of South Carolina (MUSC) received a $1.19M Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on immune signatures associated with immunotherapy response in metastatic renal cell cancer. The three-year project, effective September 1, 2025 through August 31, 2028, will be performed at MUSC's Charleston, South Carolina facility. The research aims to...
- The Medical University of South Carolina (MUSC) was awarded a $1,503,880 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will fund research into the function of the ARIH1 gene in epithelial-mesenchymal transition (EMT) and tumorigenesis. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative...
- This $1,038,931 federal Project Grant was awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant funds research conducted by The Medical University of South Carolina (MUSC) to study SETD2 deficiency and its potential to increase sensitivity to BCL-XL inhibition, which may lead to new treatment approaches. The award has a performance period from September 30, 2024 to September 29, 2028. MUSC, a public university and major...
- This federal Project Grant award in the amount of $906,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant titled "Defining and Targeting Cancer Cell-Intrinsic Vulnerabilities in Renal Cell Carcinoma" will be performed by the Medical University of South Carolina (MUSC) from August 1, 2024 to July 31, 2027. Through this funding, MUSC will conduct innovative biomedical research to study novel therapies...
- The Defense Health Agency (DHA) awarded the University of Washington a $543,285 Project Grant under the Military Medical Research and Development program (CFDA 12.420) on August 1, 2025, with a completion date of July 31, 2028. This award supports research focused on transforming rhabdomyosarcoma treatment through the development and evaluation of new FDA-approved combination therapies. The project will be conducted at the University of Washington's Seattle, Washington location under the...
- The University of Southern California received a $1,092,695 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025 through July 31, 2029. The award supports the Convergent Science Virtual Cancer Center, which will deliver biomedical research and development services focused on advancing innovative cancer research solutions for military service members and the American public. As a leading...
- The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Trustees of Columbia University in the City of New York's Health Sciences Division a $1.645 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2028. The award supports research on treating HER2 therapy-resistant brain metastasis using antidepressants, conducted at Columbia's Health Sciences Division facility in New York, NY. This project...
The Defense Health Agency (DHA) awarded The Medical University of South Carolina (MUSC) a $1.65M Project Grant on April 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research activities through April 14, 2029. The award funds basic and translational biomedical research focused on "Leveraging Epitranscriptomics and Translation Reprogramming to Prevent or Overcome Drug Resistance in Breast Cancer." The research investigates innovative approaches to address therapeutic resistance in breast cancer through epitranscriptomic mechanisms and cellular translation reprogramming, delivering hypothesis-driven research and development services designed to advance medical solutions for military-relevant health challenges and the broader American public health objectives. The Military Medical Research and Development program provides support for comprehensive biomedical research initiatives across oncology, immunotherapy, and other critical health domains through a competitive two-tier review process emphasizing technical merit and military relevance. MUSC, a major federal research institution with extensive experience in cancer research and clinical trials, will conduct the research at its facility in Charleston, South Carolina, contributing to the DHA's portfolio of cancer research investments and translational science initiatives aimed at transforming healthcare through innovative therapeutic development.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.6m | 4/2/26 |